Olema Pharmaceuticals, Inc. (OLMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$7.54+2.59%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OLMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
OLMA — officer change
Dated 2026-10-15
Director — Dr. Gorjan Hrustanovic: The resignation of a non-executive director from the board and its committees is a standard governance change with low market impact.
Why it matters: This Phase 3 readout tests palazestrant alone in advanced breast cancer. A clear benefit would support the lead drug's case.
Watch forQ1 2027 results meet the trial's main goal and show a clear benefit for palazestrant.
Also watch forResults miss the trial's main goal or show no clear benefit for palazestrant.
Why it matters: Olema had $461.1 million in cash and a $63.2 million quarterly loss. The next report can show how fast late-stage trials use cash.
Worry ifThe Nov. 9 report shows cash below $350 million or a quarterly net loss above $63.2 million.
Less concerning ifThe Nov. 9 report shows cash at or above $461.1 million and a quarterly net loss at or below $63.2 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$210 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $620 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,211 loss on $10,000 · 82.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.